CJC Pharmacie: High-Purity CJC-1295 Research Compounds & Specifications

Defining CJC Pharmacie in Preclinical Research

In analytical chemistry and molecular biology, the query 'cjc pharmacie' refers to pharmaceutical-grade CJC-1295—a synthetic tetrasubstituted 29-amino acid peptide analog of human growth hormone-releasing hormone (GHRH). Formulated specifically for laboratory investigation, CJC-1295 selectively targets the GHRH receptor on anterior pituitary somatotropes to stimulate endogenous growth hormone synthesis and release.

When procurement specialists search for pharmaceutical-grade or laboratory-grade CJC compounds, the primary concern is obtaining material with verified primary sequence integrity, absence of truncated peptide impurities, and low endotoxin burdens. PX1 Research manufactures and distributes CJC-1295 No DAC and CJC-1295 DAC engineered exclusively for in vitro cell cultures and preclinical animal models.

Molecular Structure and Mechanism of Action

CJC-1295 is derived from the first 29 amino acids of human endogenous GHRH (GHRH 1-29), often modified at key positions to enhance enzymatic resistance. Natural GHRH is rapidly inactivated in vivo by dipeptidyl peptidase IV (DPP-IV), which cleaves the peptide at the Ala2 position. To overcome this limitation, CJC-1295 incorporates specific substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27.

In vitro signaling assays demonstrate that CJC-1295 binds to the G-protein coupled GHRH receptor, initiating intracellular cyclic adenosine monophosphate (cAMP) accumulation through adenylyl cyclase activation. This signaling cascade triggers protein kinase A (PKA) phosphorylation, ultimately resulting in transcription factor activation and growth hormone transcription within pituitary somatotrope cultures. Researchers can review detailed mechanistic literature in our comprehensive PX1 Research Library.

CJC-1295 with DAC vs. CJC-1295 No DAC (Mod GRF 1-29)

A critical distinction in growth hormone secretagogues literature involves the presence or absence of the Drug Affinity Complex (DAC). CJC-1295 No DAC—frequently designated as Modified GRF 1-29—lacks the covalent conjugation tail. Consequently, it exhibits a rapid plasma elimination half-life (approximately 30 minutes in rodent models), inducing short, pulsatile bursts of GH release that closely mirror physiological pulsatility.

Conversely, CJC-1295 with DAC contains a Lysine residue modified with a maleimidopropionic acid linker. In rodent and non-human primate studies, this reactive moiety covalently binds to circulating serum albumin via a thioether bond upon administration. This albumin-binding mechanism drastically extends the peptide's terminal half-life to several days, maintaining sustained GHRH receptor stimulation. Selecting between these variants depends on whether a study seeks to model acute pulsatile secretion or continuous basal stimulation.

Preclinical Secretion Dynamics and Pituitary Somatotrope Responses

Preclinical evaluations in rodent models indicate that administration of CJC-1295 yields significant increases in circulating plasma growth hormone and downstream insulin-like growth factor 1 (IGF-1) concentrations. Unlike exogenous GH administration, GHRH receptor agonists maintain endogenous feedback loops, preventing complete suppression of baseline pituitary function.

In vitro perifusion models utilizing isolated anterior pituitary cells reveal that CJC-1295 preserves the natural intracellular calcium oscillations required for vesicular exocytosis of GH. Furthermore, animal studies assessing metabolic and body composition parameters demonstrate altered lipid oxidation rates and increased protein accretion without inducing persistent somatotrope desensitization when pulsatile exposure models are employed.

Synergistic Preclinical Protocols: Combining GHRH Analogs with GHRPs

A substantial volume of GHRH literature focuses on synergistic co-administration with growth hormone secretagogue receptor (GHSR-1a) agonists. While GHRH analogs activate the Gs-protein/cAMP pathway, ghrelin mimetics act via the Gq-protein/phospholipase C pathway to mobilize intracellular calcium.

When in vitro somatotrope assays or animal models combine a GHRH analog like CJC-1295 with a selective GHRP such as Ipamorelin, total growth hormone release exceeds the additive sum of individual compound responses. Researchers investigating secretagogue pathways often analyze dual-pathway dynamics to evaluate cellular cross-talk between cAMP and intracellular calcium signalling systems.

Comparative Analysis: GHRH Peptides in Secretagogue Research

To select the appropriate candidate for a given research protocol, investigators frequently compare CJC-1295 against other GHRH derivatives and secretagogues. While Sermorelin offers a direct truncated 1-29 sequence with rapid clearance, CJC-1295 No DAC incorporates amino acid substitutions that resist DPP-IV cleavage, offering enhanced stability in culture media. When compared alongside ghrelin receptor ligands like GHRP-6, CJC-1295 exhibits superior specificity for GHRH receptors without stimulating appetite-inducing pathways or elevated cortisol release in rodent models. Broad reviews of these secretagogue classes are available in our guide on GHRH analogs.

Reconstitution, Stability, and Handling in Laboratory Settings

CJC-1295 peptides are supplied as sterile, lyophilized (freeze-dried) cakes to maximize shelf life and stability during transport. Lyophilized vials should be stored at -20°C or -80°C upon receipt to prevent thermal degradation.

For laboratory reconstitution, researchers should utilize sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile isotonic saline, depending on the requirements of the downstream assay. The diluent should be introduced down the glass vial wall rather than directly onto the peptide powder, followed by gentle swirling without vigorous agitation. Once reconstituted, solution aliquots should be kept at 2°C to 8°C and used within a short timeframe to avoid hydrolysis and peptide aggregation.

Quality Verification: Analytical Criteria for Research Peptides

Ensuring experimental reproducibility requires rigorous quality verification of all research compounds. Obtaining pharmaceutical-grade peptides mandates multi-step analytical testing prior to experimental deployment. Laboratory managers evaluating suppliers should verify three core analytical parameters:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Establishes chromatographic purity, ensuring a minimum threshold of 98.0% main-peak area. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact monoisotopic mass and sequence identity, ruling out sequence mutations or synthesis truncations. 3. Bacterial Endotoxin Quantitation (LAL Assay): Ensures endotoxin levels remain below strict limits (<0.5 EU/mg) to avoid confounding immune activation in cell culture or animal models.

Sourcing Laboratory-Grade CJC Compounds from PX1 Research

PX1 Research is a primary USA manufacturer dedicated exclusively to high-purity research compounds for the scientific community. All peptides, including CJC-1295 variants and complementary compounds like BPC-157, undergo lot-specific testing in an ISO 17025 accredited laboratory.

Every shipment from PX1 Research includes a comprehensive, publicly verifiable Certificate of Analysis (COA) detailing RP-HPLC purity profiles, mass spec verification, and endotoxin assay results. Vials are manufactured in GMP-compliant facilities and dispatched with same-day shipping (Monday through Friday) from our California and Arizona fulfillment centers. Research institutions seeking volume orders or recurring supply agreements can register for a wholesale research account to access specialized institutional support.